Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SHOP APOTHEKE EUROPE N.V.

(SAE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

SHOP APOTHEKE EUROPE: Fast growth continues, Q1 revenues up 22.5%.

04/06/2021 | 06:00pm EDT
  • Preliminary sales growth of 22.5% in Q1 to EUR 284 million.
  • DACH segment +15%, International segment +71%.
  • Total number of active customers up 0.5 million in Q1 to 6.8 million (year-over-year up 1.8 million).

Venlo, 7 April 2021. SHOP APOTHEKE EUROPE N.V. continued to grow dynamically in the first three months of the 2021 financial year. According to preliminary unaudited calculations, total group sales rose by 22.5% to EUR 284 million after EUR 232 million in Q1 last year.

Stefan Feltens, CEO of SHOP APOTHEKE EUROPE, comments: 'We are proud that we gained another record number of new customers across Europe. We achieved this despite the absence of a cold and flu season as a result of Covid-related social distancing measures this year and the stop of a prescription drugs (Rx) bonus in Germany. Year-over-year, our number of active customers increased by 1.8 million to 6.8 million at the end of this quarter. Furthermore, with the acquisitions this quarter of SMARTPATIENT and MEDAPP we made major steps in executing our strategy to focus on improving the lives of our customers through digital medication management, while at the same time, we entered the Rx market in the Netherlands. '

In the DACH segment (Germany, Austria, Switzerland), SHOP APOTHEKE EUROPE grew sales by 15% compared to the same period the previous year. Segment sales were EUR 231 million after EUR 201 million in the first quarter of 2020. Due to the absence of a cold and flu season this year as a result of Covid-related social distancing measures, the peak of Rx orders in March 2020 when Covid started in Europe, and the stop of a bonus in Germany, Rx sales decreased by 17.2% to EUR 45 million in Q1. In the International segment (Belgium, France, Italy, the Netherlands), SHOP APOTHEKE EUROPE increased its sales in the first quarter of 2021 by 71% to EUR 53 million compared to EUR 31 million in Q1 2020.

For the full-year 2021, the Management Board of SHOP APOTHEKE EUROPE expects organically driven sales growth of around 20% or more, and an adjusted EBITDA margin in the range of a positive 2.3% - 2.8% (2020: 2.2%).

All published figures are preliminary and unaudited. SHOP APOTHEKE EUROPE N.V. will release the full interim report for the first quarter of 2021 on May 6, 2021.

ABOUT SHOP APOTHEKE EUROPE.

SHOP APOTHEKE EUROPE is one of Europe's leading and fastest-growing online pharmacies, currently operating in Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland.

Headquartered in the Dutch logistics hub of Sevenum near Venlo with locations in Cologne, Berlin, Munich, Warsaw, Milan, Paris and Tongeren, SHOP APOTHEKE EUROPE offers its customers a broad range of more than 100,000 original products at attractive prices: OTC, beauty and personal care products as well as prescription drugs, supplemented by high quality natural food and health products, low carb products and sports nutrition. Currently, more than 6.3 million active customers trust SHOP APOTHEKE EUROPE.

Since safe and reliable pharmaceutical advice are top priorities at SHOP APOTHEKE EUROPE, the e-pharmacy provides comprehensive pharmaceutical consulting services.

In preparation for the introduction of electronic prescriptions in Germany in summer 2021, the company will further improve the customer experience with focus on disease-specific digital medication management services following the acquisition of SMARTPATIENT in January 2021. This is a key part of SHOP APOTHEKE EUROPE's strategy to transform itself from a pure online retailer into a truly customer-centric e-pharmacy platform.

SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 2016 and has been part of the MDAX stock index since September 2020.

Disclaimer

Shop Apotheke Europe NV published this content on 07 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 April 2021 13:09:06 UTC.


© Publicnow 2021
All news about SHOP APOTHEKE EUROPE N.V.
05/07SHOP APOTHEKE EUROPE NV  : Barclays remains its Buy rating
MD
05/07SHOP APOTHEKE EUROPE NV  : Berenberg reaffirms its Buy rating
MD
05/07SHOP APOTHEKE EUROPE NV  : Receives a Sell rating from Kepler Cheuvreux
MD
05/06SHOP APOTHEKE EUROPE NV  : Baader Bank gives a Buy rating
MD
05/06SHOP APOTHEKE EUROPE NV  : Warburg Research sticks Neutral
MD
05/06SHOP APOTHEKE EUROPE NV  : Barclays reiterates its Buy rating
MD
05/06PRESS RELEASE  : SHOP APOTHEKE EUROPE: Strong Start -2-
DJ
05/06PRESS RELEASE : SHOP APOTHEKE EUROPE: Strong Start into 2021 with 22.4% Sales Gr..
DJ
05/06SHOP APOTHEKE EUROPE : Strong Start into 2021 with 22.4% Sales Growth and 2.0% a..
EQ
05/05SHOP APOTHEKE EUROPE NV  : Jefferies remains Neutral
MD
More news
Financials
Sales 2021 1 184 M 1 440 M 1 440 M
Net income 2021 2,65 M 3,22 M 3,22 M
Net cash 2021 10,8 M 13,2 M 13,2 M
P/E ratio 2021 1 141x
Yield 2021 -
Capitalization 2 893 M 3 516 M 3 518 M
EV / Sales 2021 2,43x
EV / Sales 2022 1,86x
Nbr of Employees 1 211
Free-Float 99,1%
Chart SHOP APOTHEKE EUROPE N.V.
Duration : Period :
Shop Apotheke Europe N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHOP APOTHEKE EUROPE N.V.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Average target price 223,50 €
Last Close Price 161,30 €
Spread / Highest target 67,4%
Spread / Average Target 38,6%
Spread / Lowest Target 8,49%
EPS Revisions
Managers and Directors
NameTitle
Stefan Feltens Chief Executive Officer
Jasper Eenhorst Chief Financial Officer
Björn H. Söder Chairman-Supervisory Board
Marc Fischer Chief Information Officer
Theresa Holler Chief Operating Officer
Sector and Competitors
1st jan.Capitalization (M$)
SHOP APOTHEKE EUROPE N.V.8.84%3 516
JD HEALTH INTERNATIONAL INC.-23.13%47 274
WALGREENS BOOTS ALLIANCE, INC.36.56%47 135
MCKESSON CORPORATION13.62%31 222
CARDINAL HEALTH, INC.5.56%17 080
HUADONG MEDICINE CO., LTD64.08%11 854